Status:
COMPLETED
Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to investigate the safety, tolerability, pharmacokinetics incl. dose proportionality, and pharmacodynamics of BI 135585 XX (Part 1), as well as the relative bioavailability...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- healthy male volunteers
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01146886
Start Date
June 1 2010
Last Update
November 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1283.1.1 Boehringer Ingelheim Investigational Site
Biberach, Germany